

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
31 March 2022 (31.03.2022)



(10) International Publication Number
WO 2022/063782 A1

(51) International Patent Classification:
C12N 15/113 (2010.01)

(21) International Application Number:
PCT/EP2021/075952

(22) International Filing Date:
21 September 2021 (21.09.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/081,633 22 September 2020 (22.09.2020) US

(71) Applicants: **ASTRAZENECA AB** [SE/SE]; SE-151-85, Södertälje (SE). **IONIS PHARMACEUTICALS, INC** [US/US]; 2855 Gazelle Ct., Carlsbad, California 92010 (US).

(72) Inventors: **LINDEN, Daniel**; ASTRAZENECA AB, SE-151-85, Södertälje (SE). **LEE, Richard**; Ionis Pharmaceuticals, Inc., 2855 Gazelle Court, Carlsbad, California 92010 (US). **BUI, Huynh-Hoa**; Ionis Pharmaceuticals, Inc., 2855 Gazelle Court, Carlsbad, California 92010 (US). **ROMEO, Stefano**; Södra Flundregatan, 42, 426 58 Göthenburg (SE).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY** et al.; Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))
— in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: METHOD OF TREATING FATTY LIVER DISEASE

(57) Abstract: The present disclosure provides methods of treating or preventing fatty liver disease and/or lowering cholesterol and LDL cholesterol levels in a subject. The present disclosure further provides methods of lowering expression of *Pleckstrin* and *Sec7 Domain Containing 3* (PSD3) in a subject.

WO 2022/063782 A1